Crohn’s Disease Drug Does Well in Trial

	Tweet

The Irish and U.S. makers of Tysabri reported Thursday that the drug - currently suspended from sale because of a possible link to a deadly disease - has produced positive results in an advanced trial for patients with Crohn’s Disease.

Elan Corp. of Ireland and Biogen Idec Inc. of Massachusetts have jointly developed Tysabri to suppress the symptoms of multiple sclerosis, which attacks the body’s central nervous system, and Crohn’s, which inflames the gastrointestinal system.

Crohn’s Disease Definition
Crohn’s disease is a chronic autoimmune disease that can affect any part of the gastrointestinal tract but most commonly occurs in the ileum (the area where the small and large intestine meet).
More information ...

Tysabri went on sale late last year in the United States after testing strongly on MS sufferers, but was withdrawn Feb. 28 after being linked to two patients who contracted a rare and usually fatal brain disease called progressive multifocal leukoencephalopathy, or PML. One of those patients died. On March 30, Elan and Biogen announced that a Crohn’s sufferer who had been taking Tysabri also had died of PML.

The Boston Globe and Wall Street Journal this month reported possible fourth and fifth cases of PML in Tysabri users, but Elan and Biogen have both declined to comment on those reports.

Elan and Biogen said Thursday that a third-phase trial of 510 Crohn’s sufferers in 114 locations, called “Encore,” had produced a reduction in symptoms within 12 weeks of treatment.

“The results of the Encore study are encouraging because patients treated with Tysabri achieved a significant improvement in symptoms of this devastating, chronic immune disease,” said Lars Ekman, president of research and development at Elan.

Ekman said the trial results were being forwarded to U.S. Food and Drug Administration officials in hopes of encouraging a decision on whether Tysabri can be returned to the market.

Investors chastened by Elan’s heavy declines since Feb. 28 gave the latest news a muted reaction Thursday. Elan shares rose 2 euro cents to 5.62 euros ($6.77) by midday on the Irish Stock Exchange, about a quarter of their value before Tysabri’s withdrawal from the U.S. market.
Source: Associated Press/AP Online

RELATED STORIES:
ACG Monthly Cimzia Controls Symptoms of Crohn’s for 24 Weeks   Drinking lots of coffee and tea can reduce the risk of chronic liver disease   Link Between Gastric Bypass Surgery and Neurological Conditions   Helicobacter pylori increases risk of lower stomach cancer, decreases risk of upper   Smoking and salt bad for stomach reflux   Hispanics face longer wait for emergency GI care   Restrictive diet unlikely to ease acid reflux   Meloxicam leads to few stomach upsets   Left-handers at greater risk of bowel problems   Drugs for Postoperative Nausea May Not Help Most Patients   “Good” bacteria help irritable bowel syndrome   Bowel disease ups blood cancer risk slightly

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]